Haleon Plc Form 6-K Summary
Business Context and Reporting Period
This Form 6-K filing by Haleon Plc covers the month of April 2026, with specific data as of March 31, 2026. Haleon is a consumer health company focused on everyday health, operating across six categories: Oral Health, Vitamins, Minerals and Supplements (VMS), Pain Relief, Respiratory Health, Digestive Health, and Therapeutic Skin Health. The company markets trusted brands including Advil, Centrum, Panadol, Sensodyne, and Voltaren.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on capital structure and voting rights.
Material Changes and Capital Structure
As of March 31, 2026, the total number of ordinary shares issued is 8,931,093,261 (par value £0.01 each). Of these, 12,548,735 shares are held as treasury shares. Consequently, the number of ordinary shares with voting rights is 8,918,544,526. This figure serves as the denominator for shareholders calculating notification obligations under the FCA's Disclosure Guidance and Transparency Rules.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for financial guidance, management outlook, specific risks, contingencies, or unusual items. The document serves as a regulatory update on share capital rather than a financial performance report.
Key Facts for Investor Verification
- Total issued shares as of March 31, 2026: 8,931,093,261.
- Treasury shares held: 12,548,735.
- Shares with voting rights: 8,918,544,526.
- Notifiable interests should be directed to company.secretary@haleon.com.
- No financial performance data (revenue, earnings, cash flow) is included in this specific filing.